"Patient"

The US FDA has approved pablizumab (Keytruda) as an adjuvant treatment for early-stage non-small cell lung cancer. In the trial, pablizumab (Keytruda) significantly prolonged cancer-free survival in patients compared to placebo.

The US FDA has approved Elacestrant, the first oral selective estrogen receptor degrader (SERD), for the treatment of patients with advanced or metastatic breast cancer who are estrogen receptor positive, HER2 negative and have an ESR1 mutation. Results of the trial showed that patients treated with Elacestrant had a 45% reduction in the risk of disease progression or death.

Stroke is the main cause of disability in Americans. More than 6.5 million Americans survive stroke every year, and most of them cannot fully recover their walking ability. Experts said that because of the difficulty in walking, these patients would not even go out to the store to buy things, but they were inactive for a long time, which led to other health problems and a spiral decline in their quality of life.

According to an announcement from Caribou Biosciences, the FDA has granted advanced therapy designation in regenerative medicine for the cutting-edge CAR-T therapy CB-010 for the treatment of relapsed or refractory large B-cell lymphoma and fast track designation for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma.

Research suggests that gender-related differences in lung cancer survival are largely determined by known prognostic factors, suggesting an opportunity to explore gender differences in treatment preference, choice and accessibility.

The US FDA has approved pemigatinib, the first targeted drug to date for patients with specific mutated blood tumours, and the results of the study show that the drug made tumours disappear completely in 79% of patients!

The European Union has recently approved Roctavian, the first gene therapy for haemophilia A. The therapy has led to a significant reduction in the average number of annual bleeds and the average number of annual clotting factor VIII transfusions in patients with this severe bleeding disorder, and has a good safety profile.

The FDA granted priority review status to Enhertu (DS-8201) for the treatment of patients with HR-positive, low HER2-expressing breast cancer, and Enhertu has enabled these patients to remain disease-free for an average of 10.1 months, with an average overall survival time of nearly two years. A decision on approval is expected to be made in the fourth quarter of this year.